Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats

Journal of Bone and Mineral Research

Volumn 13, Issue 6, 1998, Pages 1023-1031

  Westerlind, Kim Caroline ^a   Gibson, Kristin J ^a   Malone, Patricia ^a   Evans, Glenda L ^b   Turner, Russell T ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ASCORBIC ACID; CHOLESTEROL; ESTRADIOL; ESTROGEN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BONE GROWTH; BONE METABOLISM; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; ESTRONE BLOOD LEVEL; FEMALE; FEMALE GENITAL SYSTEM; MAMMARY GLAND; MORPHOMETRICS; NONHUMAN; OVARIECTOMY; RAT; STEROID HYDROXYLATION; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE SPECIFICITY; UTERUS;

ANIMALS; ANTICARCINOGENIC AGENTS; BODY WEIGHT; CELL DIVISION; CHOLESTEROL; EPITHELIAL CELLS; ESTRADIOL; ESTROGENS, CATECHOL; FEMALE; HYDROXYESTRONES; HYPERCHOLESTEROLEMIA; MAMMARY GLANDS, ANIMAL; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; STEROID 16-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; TIBIA; UTERUS;

EID: 0031746357     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.6.1023     Document Type: Article

References (44)

1. Yen SSC, Jaffe RB 1991 Reproductive Endocrinology, 3rd Ed. W.B. Saunders, Philadelphia, PA, U.S.A.
2. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J 1982 Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79:3047-3051.
3. Fishman J, Martucci C 1980 Biological properties of 16α-hydroxyestrone: Implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab 51:611-615.
4. Schneider J, Huh MM, Bradlow HL, Fishman J 1984 Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259:4840-4845.
5. Swaneck GE, Fishman J 1988 Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: Characterization and intranuclear localization. Proc Natl Acad Sci USA 85:7831-7835.
6. Martucci CP, Fishman J 1979 Impact of continuously adminstered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology 105:1288-1292.
7. Vandewalle B, Lefebvre J 1989 Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 61:239-246.
8. Bradlow HL, Michnovicz JJ 1989 A new approach to the prevention of breast cancer. Proc Royal Soc Edinburgh 95B:77.
9. Sepkovic DW, Bradlow HL, Ho G, Hankinson SE, Gong L, Osborne MP, Fishman J 1995 Estrogen metabolite ratios and risk assessment of hormone-related cancers: Assay validation and prediction of cervical cancer risk. Ann NY Acad Sci 768: 312-316.
10. Osborne MP, Bradlow HL, Wong GYC, Telang NT 1993 Upregulation of estradiol C16α-hydroxylation in human breast tissue: A potential biomarker of breast cancer risk. J Natl Cancer Inst 85:1917-1920.
11. Kabat GC, Chang CJ, Sparano JA, Sepkovic DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL 1997 Urinary estrogen metabolites and breast cancer: A case-control study. Cancer Epidemiol Biomarkers Prev 6:505-509.
12. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J 1985 Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: A possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA 82:6295-6299.
13. Coker AL, Crane MM, Sticca RP, Sepkovic DW 1997 Re: Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst 89:89-90.
14. Adlercreutz H, Fotsis T, Hockerstedt K, Hamalainen E, Bannwart C, Bloigu S, Valtonen A, Ollus A 1989 Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem 34:527-530.
15. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E 1994 Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 86:1076-1082.
16. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP 1996 2-Hydroxyestrone: The "good" estrogen. J Endocrinol 150: S259-S265.
17. Lim SK, Won YJ, Lee JH, Kwon SH, Lee EJ, Kim KR, Lee HC, Hah KB, Chung BC 1997 Altered hydroxylation of estrogen in patients with postmenopausal osteopenia. J Clin Endocrinol Metab 82:1001-1006.
18. Hodge J, Roodman-Weiss J, Lyss C, Wagner D, Klug T, Civitelli R 1995 Increased inactive estrogen metabolites in urine of early postmenopausal women with low bone density. J Bone Miner Res 10:S444.
19. Leelawattana R, Ziambaras K, Lyss C, Roodman-Weiss J, Wagner D, Klug T, Civitelli R 1997 Estrogen metabolites in urine of early postmenopausal women correlate with bone density and rate of bone loss. J Bone Miner Res 12:S132.
20. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR 1996 Bone mineral density and risk of breast cancer in older women. J Am Med Assoc 276:1404-1408.
21. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D, Felson DT 1997 Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611-617.
22. Westerlind KC, Sarkar G, Bolander ME, Turner RT 1995 Estrogen receptor mRNA is expressed in vivo in rat calvarial periosteum. Steroids 60(8):484-487.
23. Turner RT, Backup P, Sherman PH, Hill E, Evans GL, Spelsberg TC 1992 Mechanism of action of estrogen on intramembranous bone formation: Regulation of osteoblast differentiation and activity. Endocrinology 131:883-889.
24. Hoyland JA, Mee AP, Baird P, Braidman IP, Mawer EB, Freemont AJ 1997 Demonstration of estrogen receptor mRNA in bone using in situ reverse-transcriptase polymerase chain reaction. Bone 20:87-92.
25. Turner RT, Riggs BL, Spelsberg TC 1994 Skeletal effects of estrogen. Endocr Rev 15:275-300.
26. Gallagher JC 1996 Estrogen: prevention and treatment. In: Marcus R, Feldman D, and Kelsey J (eds.) Osteoporosis. Academic Press, New York, NY, U.S.A.
27. Westerlind KC, Wakley GK, Evans GL, Turner RT 1993 Estrogen does not increase bone formation in growing rats. Endocrinology 133:2924-2934.
28. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
29. Klug TL, Bradlow HL, Sepkovic DW 1994 Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16α-hydroxyestrone in urine. Steroids 59:648-655.
30. Pitelka DR 1988 The mammary gland. In: Weiss L (ed.) Cell and Tissue Biology. Urban & Schwarzenberg, Baltimore, MD, U.S.A., pp. 877-898.
31. Wronski TJ, Cintron M, Dann LM 1988 Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Res 43:179-183.
32. Turner RT, Vandersteenhoven JJ, Bell NH 1987 The effects of ovariectomy and 17β-estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res 2:61-66.
33. Wronski TJ, Walsh CC, Iganszewski LA 1986 Histological evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone 7:119-123.
34. Wronski TJ, Dann LM, Scott KS, Crooke LR 1989 Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats. Endocrinology 125: 810-816.
35. Evans GL, Bryant HU, Magee DE, Turner RT 1996 Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137:4139-4144.
36. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD 1995 Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:2435-2441.
37. Denis I, Pointillart A, Lieberherr M 1994 Cell stage-dependent effects of ascorbic acid on cultured porcine bone cells. Bone Miner 25:149-161.
38. Ganta DR, McCarthy MB, Gronowicz GA 1997 Ascorbic acid alters collagen integrins in bone culture. Endocrinology 138: 3606-3612.
39. Turner RT, Wakley GK, Hannon KS, Bell NH 1988 Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122:1146-1150.
40. Evans GL, Bryant HU, Magee D, Sato M, Turner RT1994 The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134:2283-2288.
41. Jimenez MA, Magee DE, Bryant HU, Turner RT 1997 Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats. Endocrinology 138:1794-1800.
42. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC 1988 Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297-301.
43. Fornander T, Rutqvist LE, Sjoberg HE, Blomqvist L, Mattsson A, Glas U 1990 Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019-1024.
44. Mack TM, Ross RK 1989 Risks and benefits of long-term treatment with estrogens. Schweiz Med Wochenschr 119:1811-1820.